SEC-FDA Information-Sharing MOU: Implications for Pharma and Biotech - Morgan Lewis
Why now
Thesis: SEC-FDA MOU could speed regulatory review.
Catalyst to watch: Implementation of information-sharing.
Main risk: Structural item with slow impact.
Why it matters
SEC-FDA information-sharing MOU could speed regulatory review and enforcement, a structural item for pharma and biotech.
Sources
- googlenews · news.google.com · 2026-09-21 18:24 UTC
- googlenews · news.google.com · 2026-09-21 18:24 UTC